METFORMIN AND DICHOLOROACETATE COMBINATION EXERT A SYNERGISTIC EFFECT ON CELL VIABILITY OF ORAL SQUAMOUS CELL CARCINOMA

IF 0.2 Q4 OTORHINOLARYNGOLOGY

ENT Updates Pub Date : 2019-08-08 DOI:10.32448/ENTUPDATES.569464

Ş. Inanç, Didem Keleş, G. Eskiizmir, Y. Başbınar, G. Oktay

{"title":"METFORMIN AND DICHOLOROACETATE COMBINATION EXERT A SYNERGISTIC EFFECT ON CELL VIABILITY OF ORAL SQUAMOUS CELL CARCINOMA","authors":"Ş. Inanç, Didem Keleş, G. Eskiizmir, Y. Başbınar, G. Oktay","doi":"10.32448/ENTUPDATES.569464","DOIUrl":null,"url":null,"abstract":"Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line. Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method. Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells. Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.","PeriodicalId":41744,"journal":{"name":"ENT Updates","volume":null,"pages":null},"PeriodicalIF":0.2000,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ENT Updates","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32448/ENTUPDATES.569464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: To assess the effects of Metformin, Dichloroacetate (DCA) and their combination on cell viability in oral squamous cell carcinoma, UPCI-SCC-131 cell line. Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104 cells/well) and were treated with Metformin (1-16mM) and/or DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used to monitor real time cell viability. In addition, drug combination index was analyzed with CompuSyn software according to Chou-Talalay method. Results: Half-maximal inhibitory concentrations (IC50) of Metformin and DCA were found to be 3mM and 23mM, respectively, for 72 hours. CI values (0.76-0.80) in all combination groups below 1 indicated that Metformin/DCA combination had a moderate synergistic effect on cell viability in UPCI-SCC-131 cells. Discussion: Metformin/DCA combination synergistically decreased the cell viability of UPCI-SCC-131 cells. Therefore, a combined application of Metformin and DCA may be considered as a candidate therapy for the “drug repositioning” of the treatment of oral cavity cancer.

查看原文本刊更多论文

二甲双胍联合二氯乙酸对口腔鳞状细胞癌细胞活力有协同作用

目的:探讨二甲双胍、二氯乙酸(DCA)及其联合用药对口腔鳞状细胞癌UPCI-SCC-131细胞株细胞活力的影响。方法:将UPCI-SCC-131细胞置于96个e板(1x104个/孔)中，二甲双胍(1-16mM)和/或DCA (15-120mM)处理24-48-72h。采用xCELLigence SP系统实时监测细胞活力。根据Chou-Talalay法，采用CompuSyn软件对联合用药指标进行分析。结果:二甲双胍和DCA的半最大抑制浓度(IC50)分别为3mM和23mM，作用72小时。在所有低于1的联合组中，CI值(0.76-0.80)表明二甲双胍/DCA联合对UPCI-SCC-131细胞的细胞活力有中等的协同作用。讨论:二甲双胍/DCA联合使用可协同降低UPCI-SCC-131细胞的细胞活力。因此，二甲双胍与DCA联合应用可能被认为是口腔癌治疗“药物重新定位”的候选疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ENT Updates OTORHINOLARYNGOLOGY-

自引率

0.00%

发文量

审稿时长

14 weeks

文献相关原料

公司名称	产品信息	采购帮参考价格